H35.3
Conditions
Interventions
Group 1: switch from intravitreal bevacizumab (at least 3 monthly injections) to 3 monthly injections of ranibizumab.
No further data besides the clinical routine will be collected.
Group 2: switch fr
Sponsors
Universitäts-Augenklinik Freiburg
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: intravitreal injections for treatment of AMD, switch of medication after at least 3 monthly injections to the other medication after max. 100 days, at least 3 monthly injections after switch, data available for visual acuity before,a fter, and at time of switch
Exclusion criteria
Exclusion criteria: indications other than AMD, other reasons/comorbidity for impaired visual acuity, intraocular surgery during time of study, therapy regime other than mentioned under inclusion criteria, macular hemorrhage during time of study, missing data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| regression analysis to look for prognostic factors before and after switch of medication: age, injections before switch, medication before switch, visual acuity (5m distant VA) and retinal thickness (central macular thickness measured by OCT (optical coherence tomography)) at the time of switch | — |
Secondary
| Measure | Time frame |
|---|---|
| change of visual acuity (5m distance VA) and retinal thickness (central macular thickness measured by OCT) 4 weeks after 3 intravitreal injections after switching the medication | — |
Countries
Germany
Contacts
Public ContactChristoph Ehlken
Universitäts-Augenklinik Freiburg
Outcome results
None listed